SCHEMBL15023030

SCHEMBL15023030

NC(c1cccc(Cl)c1)c1ncccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.41
▸ TRPM8 Q7Z2W7 12/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ TRPA1 O75762 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ S1PR2 O95136 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ OPRL1 P41146 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14405536 1.00 GAA (0.41) GAATRPM8HSD11B1TRPA1MEN1
SCHEMBL14405578 0.84 TRPM8 (0.53) TRPM8HSD11B1ALDH1A1
SCHEMBL15022557 0.84 TRPM8 (0.53) TRPM8HSD11B1ALDH1A1
SCHEMBL14405577 0.84 TRPM8 (0.42) TRPM8
SCHEMBL15021334 0.84 TRPM8 (0.42) TRPM8
SCHEMBL15024098 0.84 TRPM8 (0.43) TRPM8HSD11B1
SCHEMBL14405627 0.84 TRPM8 (0.43) TRPM8HSD11B1
SCHEMBL14405576 0.84 TRPM8 (0.40) TRPM8
SCHEMBL14405534 0.83 TRPM8 (0.53) TRPM8LMNA
SCHEMBL15021812 0.83 TRPM8 (0.53) TRPM8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096527-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2015-08-04 — — US disclosed
US-20140171406-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2014-06-19 — — US disclosed
US-20140171639-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2014-06-19 — — US disclosed
US-8710043-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2014-04-29 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171639-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 GAA 1524/4885TRPM8 1/4885HSD11B1 4726/4885
US-20140171406-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 GAA 1524/4885TRPM8 1/4885HSD11B1 4726/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 GAA 1524/4885TRPM8 1/4885HSD11B1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback